Drugs / BPI-460372
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05789602 | Apr 2023 → Apr 2025 overdue | neoplasm | Betta Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPI-460372 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05789602 ↗ |
| Route | Oral | “Oral tablets taken in escalating levels to determine MTD/RP2D.” NCT05789602 ↗ |